<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03944369</url>
  </required_header>
  <id_info>
    <org_study_id>K017-119</org_study_id>
    <nct_id>NCT03944369</nct_id>
  </id_info>
  <brief_title>VITORA: Clinical Study to Evaluate the Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointestinal Tracts Are Colonized With Multiple Drug-resistant Organisms</brief_title>
  <acronym>VITORA</acronym>
  <official_title>A Randomized, Open-Label, Prospective, Parallel Group, 2-Part Clinical Food Study to Assess the Safety, Tolerability, and Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointesinal Tracts Are Colonized With Multiple Drug-resistant Organisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaleido Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaleido Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, open-label, clinical study aims to explore the safety and tolerability of
      KB109, a novel glycan, versus an observational control group on the gut microbiome in
      subjects whose gastrointestinal tracts are colonized with multiple drug-resistant organisms.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2019</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Randomized, Open-Label, Prospective, Parallel Group, 2-Part Study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of product-related treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Day -7 through Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Day -7 through Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Bristol Stool Scale (BSS) through the collection of daily patient questionnaires.</measure>
    <time_frame>Day -7 through Day 42]</time_frame>
    <description>Evaluate the effect of KB109 on self-report questionnaires including the Bristol Stool Scale, an assessment of stool consistency on a scale from 1 (separate hard lumps, like nuts, hard to pass) through 7 (watery, no solid pieces, entirely liquid)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Proportion of subjects with a reduction from baseline on Day 28 in the relative abundance of taxa of interest (Enterobacteriaceae, Enterococcus, and C. difficile, individually) as measured by metagenomic sequencing.</measure>
    <time_frame>Day -1 to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Vancomycin-Resistant Enterococcus, Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae, or Carbapenem-Resistant Enterobacteriaceae Colonized Subjects</condition>
  <arm_group>
    <arm_group_label>Observational Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The observational control arm is an observational control group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KB109</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>KB109 is a novel glycan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>KB109</intervention_name>
    <description>KB109 is a novel glycan</description>
    <arm_group_label>KB109</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Observational Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be male or female, ≥18 years of age

          -  Positive stool culture for at least one of these three organisms: VRE, ESBLE or CRE

          -  Be willing and able to give informed consent

          -  If taking probiotic or prebiotic dietary supplements, usage must be consistent within
             7 days prior to the run-in phase and willing to remain consistent throughout the study

          -  If subject is female: subject is surgically sterile or post-menopausal (12 months with
             no menses without an alternate medical cause); or if subject is a female of
             childbearing potential, must have a negative urine pregnancy test at Screening, must
             not be lactating, and must agree to abstain from sexual activity or agree to use one
             highly effective method of contraception for the duration of the study

        Exclusion Criteria:

          -  Planned escalation of immunosuppression

          -  Neutropenia (≤500 absolute neutrophil count per μL)

          -  Allogenic stem cell transplant recipients with ongoing gastrointestinal disease

          -  Rapidly progressive or terminal illness

          -  Hemodynamic instability, or any other significant systemic, unstable or untreated
             disease

          -  Currently receiving or anticipated to require systemic (oral or IV anti-infective) or
             gut-directed antibacterial therapy

          -  Recent history of the following conditions requiring medical attention: known or
             suspected gastrointestinal (GI) infection (e.g., viral or bacterial gastroenteritis)
             or inflammatory bowel disease

          -  Major intra-abdominal surgery related to the bowel within the 3 months prior to Run-In

          -  Receiving total parenteral nutrition

          -  Contraindications, sensitivity, or known allergy to the use of the study product or
             its components

          -  Individuals who, in the opinion of the Investigator, are considered to be poor
             attendees or unlikely for any reason to be able to comply with the study procedures
             (e.g., planned procedures)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Wingertzahn, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kaleido Boisciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Wingertzahn, PhD</last_name>
    <phone>(617) 674-9000</phone>
    <email>clinicalstudies@kaleido.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Harbor UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>424-271-0297</phone>
      <email>joey.fragoso@lundquist.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allen W Graham</last_name>
      <phone>404-712-2962</phone>
      <email>allen.w.graham@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Augusta Universtiy</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>301912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>idresearch@augusta.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Newland Immunology Center of Excellence; Providence Hospital</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Dobrina.Yankova@acension.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stony Brook University</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ajish.pallai@stonybrookmedicine.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atrium Health's Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>daxita.patel@carolinashealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>bnw6@pitt.edu</email>
    </contact>
    <contact_backup>
      <email>mhn5@pitt.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>mehriban.mammadova@uth.tmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 8, 2019</study_first_submitted>
  <study_first_submitted_qc>May 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2019</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microbiome</keyword>
  <keyword>Antibiotic resistance</keyword>
  <keyword>Carbapenem-Resistant Enterobacteriaceae (CRE)</keyword>
  <keyword>Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae (ESBLE)</keyword>
  <keyword>Vancomycin-resistant Enterococcus (VRE)</keyword>
  <keyword>Multi Drug Resistant Organism (MDRO)</keyword>
  <keyword>Drug resistant</keyword>
  <keyword>Kaleido</keyword>
  <keyword>VITORA</keyword>
  <keyword>KB109</keyword>
  <keyword>Microbiome Metabolic Therapy (MMT)</keyword>
  <keyword>Oligosaccharide</keyword>
  <keyword>Glycan</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

